N
Naoto T. Ueno
Researcher at University of Texas MD Anderson Cancer Center
Publications - 390
Citations - 13778
Naoto T. Ueno is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Inflammatory breast cancer. The author has an hindex of 59, co-authored 389 publications receiving 11623 citations. Previous affiliations of Naoto T. Ueno include University of Texas Health Science Center at Houston & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.
Clinton Yam,Er-Yen Yen,Jeffrey T. Chang,Roland L. Bassett,Gheath Alatrash,Haven R. Garber,Lei Huo,Fei Yang,Anne V. Philips,Qingqing Ding,Bora Lim,Naoto T. Ueno,Kasthuri Kannan,Xiangjie Sun,Baohua Sun,Edwin Roger Parra Cuentas,William Fraser Symmans,Jason B White,Elizabeth Ravenberg,Sahil Seth,Jennifer L. Guerriero,Gaiane M. Rauch,Senthil Damodaran,Jennifer K. Litton,Jennifer A. Wargo,Gabriel N. Hortobagyi,Andrew Futreal,Ignacio I. Wistuba,Ryan Sun,Stacy L. Moulder,Elizabeth A. Mittendorf,Elizabeth A. Mittendorf +31 more
TL;DR: In this article, the authors investigated the effect of increasing tumor-infiltrating lymphocytes (TILs) on pathologic complete response (pCR) in patients with triple-negative breast cancer.
Journal ArticleDOI
MEK1/2 Inhibitor Selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15-dependent Manner in a Mouse Xenograft Model
Chandra Bartholomeusz,Tetsuro Oishi,Tetsuro Oishi,Hitomi Saso,Ugur Akar,Ping Liu,Kimie Kondo,Anna Kazansky,Savitri Krishnamurthy,Jangsoon Lee,Francisco J. Esteva,Junzo Kigawa,Naoto T. Ueno +12 more
TL;DR: The findings indicate that the MEK–ERK pathway is a potential target for EGFR-overexpressing CCC and indicate that selumetinib and erlotinib are worth exploring as therapeutic agents for CCC.
Journal ArticleDOI
Phase II Study of Gonadotropin-Releasing Hormone Analog for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
Yee Chung Cheng,Yee Chung Cheng,Mariko Takagi,Andrea Milbourne,Richard E. Champlin,Naoto T. Ueno +5 more
TL;DR: Leuprolide did not preserve ovarian function in patients who underwent HSCT using either myeloablative or nonmyeloablatives regimens, and other measures that protect ovarian function need to be investigated.
Journal ArticleDOI
Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy
Hiroaki Itamochi,Junzo Kigawa,Yasunobu Kanamori,Tetsuro Oishi,Chandra Bartholomeusz,Rita Nahta,Francisco J. Esteva,Nour Sneige,Naoki Terakawa,Naoto T. Ueno +9 more
TL;DR: E1A gene therapy, because of its ability to stabilize wild-type p53, is worth exploring as a treatment modality for women with ovarian CCC, which typically expresses wild- type p53.
Journal ArticleDOI
Identification of frequent somatic mutations in inflammatory breast cancer
Naoko Matsuda,Bora Lim,Ying Wang,Savitri Krishnamurthy,Wendy A. Woodward,Ricardo H. Alvarez,Anthony Lucci,Vicente Valero,James M. Reuben,Funda Meric-Bernstam,Naoto T. Ueno +10 more
TL;DR: TP53, PIK3CA, and ERBB2 were detected as three major somatic mutations in metastatic inflammatory breast cancer patients, the first report of higher frequency of ER BB2 mutation ininflammatory breast cancer, especially in the HR+ subtype.